The IRAK4 inhibitor CA-4948 is currently under investigation in R/R CLL and other indolent B-cell malignancies as a single agent or in combination with ibrutinib (NCT03328078). This evidence concerns the gene IRAK4 and B-cell chronic lymphocytic leukemia.